Physeon Receives Institutional Review Board Approval to Commence US “VIVA” Trial for Veinplicity at Second Site Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater...

Physeon Receives Institutional Review Board Approval to Commence US "VIVA" Trial for Veinplicity Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater...

Lexington Completes IRB Submission in Preparation for Clinical Study VANCOUVER, British Columbia, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device...